Related Experiment Video
Updated: Jul 19, 2026
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects
Lainie Martin1, Russell J Schilder
1From Fox Chase Cancer Center, Philadelphia, Pennsylvania, PA 19103, USA. L_Martin@fccc.edu
Abstract:
Although significant improvements in standard therapy for ovarian carcinoma have been made over the past decade, current treatment is limited by the development of resistance to cytotoxic chemotherapy, and most women ultimately die of the disease. New knowledge of the biology of ovarian cancer has led to the identification of potential molecular targets that are differentially expressed in normal cells versus cancer cells, and advances in pharmacology have led to the development of novel agents that work differently from traditional cytotoxic chemotherapy by exploiting these targets. Many of these agents are being evaluated in clinical trials. This article discusses molecular targets that are important in ovarian carcinoma, including angiogenesis, tyrosine kinases, mitogen-activated protein kinases, and phosphatidylinositol-like kinases such as mammalian target of rapamycin, and the proteosome. This article reviews novel non-cytotoxic agents that target these pathways and are currently being evaluated in ovarian carcinoma treatment.
Insights
New ovarian cancer therapies target molecular pathways, offering hope beyond traditional chemotherapy. These novel agents exploit specific cancer cell targets to overcome treatment resistance and improve outcomes for patients with ovarian carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Standard chemotherapy for ovarian carcinoma faces limitations due to drug resistance, leading to poor patient outcomes.
- Recent advances in understanding ovarian cancer biology have identified novel molecular targets.
- Traditional cytotoxic chemotherapy is increasingly being supplemented by targeted therapies.
Purpose of the Study:
- To review key molecular targets in ovarian carcinoma.
- To discuss novel non-cytotoxic agents targeting these pathways.
- To summarize the current clinical evaluation of these novel agents in ovarian cancer treatment.
Main Methods:
- Review of current literature on ovarian cancer molecular targets.
- Identification and discussion of novel non-cytotoxic therapeutic agents.
- Summary of ongoing clinical trials for these agents.
Main Results:
- Several molecular targets, including angiogenesis, tyrosine kinases, mitogen-activated protein kinases, and the proteasome, are crucial in ovarian carcinoma.
- Novel non-cytotoxic agents targeting these pathways are under investigation.
- These agents represent a promising new direction for ovarian cancer treatment.
Conclusions:
- Targeting specific molecular pathways offers a promising strategy to overcome chemotherapy resistance in ovarian cancer.
- Novel non-cytotoxic agents are being actively evaluated in clinical trials for ovarian carcinoma.
- These targeted therapies have the potential to significantly improve treatment efficacy and patient survival in ovarian carcinoma.
More Related Videos
09:40Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers